Today: 9 June 2026
Salesforce stock rises as tech steadies after soft jobs data; CRM investors eye Friday payrolls
7 January 2026
1 min read

Salesforce stock rises as tech steadies after soft jobs data; CRM investors eye Friday payrolls

New York, January 7, 2026, 15:08 ET — Regular session

  • Salesforce shares rose 1.6% to $267.13 in afternoon trading, after swinging between $261.52 and $267.81.
  • U.S. stocks were mixed as investors digested fresh labor-market data and recalibrated rate expectations.
  • Traders are watching Friday’s U.S. payrolls report and the pace of Salesforce’s AI monetization into 2026.

Salesforce (CRM.N) shares rose 1.6% to $267.13 in afternoon trading on Wednesday, recovering some ground after early volatility, with about 3.7 million shares changing hands.

The uptick came as technology shares extended gains from the prior session, helping keep the S&P 500 and Nasdaq in positive territory even as investors tested how much more they want to pay for growth. “The economic news sort of fueled a little bit of profit taking,” Robert Pavlik, a senior portfolio manager at Dakota Wealth, said. Reuters

Data released on Wednesday showed U.S. private payrolls rose by 41,000 in December, undershooting forecasts, while job openings in November fell more than expected. Economists and traders have been looking to Friday’s nonfarm payrolls report for the next signal on the labor market and the Federal Reserve’s path.

For Salesforce, the backdrop matters because its core customers are big employers and big spenders — and because the stock trades like a long-duration asset, sensitive to shifts in rates. The company has leaned hard into “AI agents,” software designed to perform tasks with less human input, as it tries to justify premium pricing and defend share in enterprise applications.

In its latest quarterly update in December, Salesforce raised its fiscal 2026 revenue outlook to $41.45 billion-$41.55 billion and pointed to stronger demand for its Agentforce and Data 360 products. Marc Benioff called them “momentum drivers” after the company said the offerings reached nearly $1.4 billion in annual recurring revenue, a subscription-sales measure tracked by investors. Salesforce Investor Relations

Other large-cap software names were also higher on the day, including Microsoft, Oracle, ServiceNow and Adobe.

Salesforce is also set to pay a quarterly cash dividend of $0.416 per share on January 8, according to a company statement.

But the setup is not clean. If enterprise buyers slow purchases or push out renewals, AI pilots can take longer to turn into paid subscriptions, and rivals with broad stacks — from Microsoft to Oracle — have been aggressive in bundling AI features.

What comes next is less about Salesforce’s chart than the calendar: Friday’s U.S. jobs report, then the next round of earnings season check-ins for signs that AI demand is turning into steady, billable revenue rather than talk.

Stock Market Today

  • GSK to Acquire Nuvalent for $10.6 Billion to Boost Oncology Pipeline
    June 9, 2026, 9:41 AM EDT. GSK announced a $10.6 billion cash acquisition of U.S.-based Nuvalent, offering $124 per share, a 40% premium. The purchase aims to strengthen GSK's oncology portfolio ahead of patent expiries on key HIV treatments. Nuvalent awaits FDA decisions on two lung cancer drugs, zidesamtinib and neladalkib, with potential 2027 market entry. The deal also includes earlier-stage cancer treatments, including NVL-330. Nuvalent shares rose nearly 39% premarket, while GSK shares slipped 1.4%. GSK plans to finance the deal through debt and cash, expecting sales and profit boosts from 2027 and 2029, respectively, without impacting its credit rating. The acquisition intensifies GSK's lung cancer market presence, competing with firms like AstraZeneca, Roche, and Pfizer.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Europa Clipper’s UV look at Comet 3I/ATLAS backs water-ice call as radio “technosignature” scan finds none
Previous Story

Europa Clipper’s UV look at Comet 3I/ATLAS backs water-ice call as radio “technosignature” scan finds none

AMD stock slips after hours as CES AI chip blitz sets up Feb. 3 earnings test
Next Story

AMD stock slips after hours as CES AI chip blitz sets up Feb. 3 earnings test

Go toTop